New Positive Data On Levemir, NovoRapid

Levemir improves glucose control without weight gain and hypoglycemia.

Novo Nordisk on Friday presented new data which shows that its rapid-acting insulin Levemir and NovoRapid improve metabolic control and reduce the rate of patients with type one diabetes who get low blood sugar levels, without causing undesirable weight gain.

Doctor Anne Dornhorst from Imperial College, London, England, said: "Weight gain can have serious consequences for people with diabetes and effective management of diabetes with insulin therapy can often be a cause of increased body weight. These results show that the use of this basal-bolus regimen is providing excellent disease management whilst not causing undesirable weight gain."

The results are based on data from 179 people with type one diabetes from a subgroup of the German arm of the PREDICTIVE study, one of the largest global observational studies ever conducted in diabetes.

The company said these findings further support data presented at the American Diabetes Association congress earlier this year from over 10,000 patients in the German arm of the PREDICTIVE study. These results demonstrated that Levemir improved glycemic control and reduced the risk of hypoglycemia in people with type one and type two diabetes without causing weight gain.

Further data, also presented at EASD, confirm the once-daily action of Levemir. These data are from the first head-to-head study of the time-action profiles of Levemir and insulin glargine in patients with type two diabetes.

The study concluded that there were no substantial differences in the shape of the profiles, duration of action and dose-response relationship between both insulin’s.

Source: Diabetes In Control: The data was presented at the European Association for the Study of Diabetes annual congress in Copenhagen.